FINGOLIMOD HYDROCHLORIDE

/static/temp/default.svg

Search structure


Trade Names	GILENYA
Synonyms	FTY-720 HYDROCHLORIDE FTY720 FTY720 HYDROCHLORIDE Fingolimod Fingolimod (as hydrochloride) Fingolimod hcl Fingolimod hydrochlorid Fingolimod hydrochloride Gilenia Gilenya
Status
Molecule Category	Salt-form
UNII	G926EC510T
EPA CompTox	DTXSID00167364
Parent Compound:	FINGOLIMOD


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	SWZTYAVBMYWFGS-UHFFFAOYSA-N
Smiles	CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1.Cl
InChI	InChI=1S/C19H33NO2.ClH/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22;/h9-12,21-22H,2-8,13-16,20H2,1H3;1H

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C19H34ClNO2
Molecular Weight	343.94
AlogP	3.2
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	3.0
Number of Rotational Bond	12.0
Polar Surface Area	66.48
Molecular species	BASE
Aromatic Rings	1.0
Heavy Atoms	22.0

Bioactivity

Mechanism of Action	Action	Reference
Sphingosine 1-phosphate receptor agonist	AGONIST	DailyMed

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Membrane receptor Family A G protein-coupled receptor Small molecule receptor (family A GPCR) Lipid-like ligand receptor (family A GPCR) EDG receptor	3000	-	-	-	-

Assay Description	Organism	Bioactivity	Reference
Effect on mouse allogenic mixed lymphocyte reaction (MLR)	Mus musculus	6.1 nM
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging	Homo sapiens	-1.5 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	6.389 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.05 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.05 %

Cross References

Resources	Reference
ChEBI	63112
ChEMBL	CHEMBL544665
FDA SRS	G926EC510T
PubChem	107969
SureChEMBL	SCHEMBL81362

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).